Outlook on the Global Oncology/Cancer Drugs Market to 2025 | by Drug Class Type & Indication - ResearchAndMarkets.com

DUBLIN--()--The "Oncology/Cancer Drugs Market by Drug Class Type and Indication: Global Opportunity Analysis and Industry Forecast, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

According to this report, the market was valued at $97,401 million in 2017, and is projected to reach $176,509 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

The key drivers of the global oncology/cancer drugs market are surge in geriatric population and rise in collaborations & partnerships to facilitate drug development. In addition, surge in prevalence of cancer and increase in healthcare expenditure have significantly contributed toward the growth of this market. Increase in number of pipeline drugs along with high potential of emerging economies are further expected to provide lucrative opportunities for market expansion. However, adverse effects related to cancer drugs impede the market growth.

The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Based on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers.

Regionally, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

North America was the leading revenue contributor to the global market in 2017, garnering nearly 47.65% of the total market share, owing to high adoption rate of cancer drugs. However, Asia-Pacific is expected to grow at the highest CAGR of 9.5% from 2018 to 2025, owing to increase in disposable income; surge in research, development, & innovation activities; and rise in awareness related to different cancers.

The report provides an extensive competitive analysis and profiles of the key market players such as Amgen Inc., Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.

Key Findings of the Oncology/Cancer Drugs Market

  • North America occupied nearly half share of the global oncology/cancer drugs market in 2017.
  • The immunotherapy segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • The breast cancer segment accounted for less than one-seventh share of the market in 2017.
  • Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.

For more information about this report visit https://www.researchandmarkets.com/r/f4qexs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900